Your browser doesn't support javascript.
loading
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.
Heinze, Karolin; Cairns, Evan S; Thornton, Shelby; Harris, Bronwyn; Milne, Katy; Grube, Marcel; Meyer, Charlotte; Karnezis, Anthony N; Fereday, Sian; Garsed, Dale W; Leung, Samuel C Y; Chiu, Derek S; Moubarak, Malak; Harter, Philipp; Heitz, Florian; McAlpine, Jessica N; DeFazio, Anna; Bowtell, David D L; Goode, Ellen L; Pike, Malcolm; Ramus, Susan J; Pearce, C Leigh; Staebler, Annette; Köbel, Martin; Kommoss, Stefan; Talhouk, Aline; Nelson, Brad H; Anglesio, Michael S.
Afiliação
  • Heinze K; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
  • Cairns ES; OVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.
  • Thornton S; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
  • Harris B; OVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.
  • Milne K; Molecular and Cellular Immunology Core (MCIC), Deeley Research Centre, BC Cancer, Victoria, Canada.
  • Grube M; Molecular and Cellular Immunology Core (MCIC), Deeley Research Centre, BC Cancer, Victoria, Canada.
  • Meyer C; Molecular and Cellular Immunology Core (MCIC), Deeley Research Centre, BC Cancer, Victoria, Canada.
  • Karnezis AN; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
  • Fereday S; OVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.
  • Garsed DW; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
  • Leung SCY; Department of Pathology and Laboratory, UC Davis Medical Center, Sacramento, California.
  • Chiu DS; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Moubarak M; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Harter P; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Heitz F; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • McAlpine JN; OVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.
  • DeFazio A; OVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.
  • Bowtell DDL; Kliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany.
  • Goode EL; Kliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany.
  • Pike M; Kliniken Essen Mitte, Department of Gynecology and Gynecologic Oncology, Essen, Germany.
  • Ramus SJ; Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Pearce CL; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
  • Staebler A; OVCARE - British Columbia's Gynecological Cancer Research Program, BC Cancer, Vancouver General Hospital, and the University of British Columbia, Vancouver, British Columbia, Canada.
  • Köbel M; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Kommoss S; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Talhouk A; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Nelson BH; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
  • Anglesio MS; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Clin Cancer Res ; 29(17): 3471-3483, 2023 09 01.
Article em En | MEDLINE | ID: mdl-37339172
ABSTRACT

PURPOSE:

Endometrioid ovarian carcinoma (ENOC) is the second most-common type of ovarian carcinoma, comprising 10%-20% of cases. Recently, the study of ENOC has benefitted from comparisons to endometrial carcinomas including defining ENOC with four prognostic molecular subtypes. Each subtype suggests differential mechanisms of progression, although tumor-initiating events remain elusive. There is evidence that the ovarian microenvironment may be critical to early lesion establishment and progression. However, while immune infiltrates have been well studied in high-grade serous ovarian carcinoma, studies in ENOC are limited. EXPERIMENTAL

DESIGN:

We report on 210 ENOC, with clinical follow-up and molecular subtype annotation. Using multiplex IHC and immunofluorescence, we examine the prevalence of T-cell lineage, B-cell lineage, macrophages, and populations with programmed cell death protein 1 or programmed death-ligand 1 across subtypes of ENOC.

RESULTS:

Immune cell infiltrates in tumor epithelium and stroma showed higher densities in ENOC subtypes with known high mutation burden (POLEmut and MMRd). While molecular subtypes were prognostically significant, immune infiltrates were not (overall survival P > 0.2). Analysis by molecular subtype revealed that immune cell density was prognostically significant in only the no specific molecular profile (NSMP) subtype, where immune infiltrates lacking B cells (TILB minus) had inferior outcome (disease-specific survival HR, 4.0; 95% confidence interval, 1.1-14.7; P < 0.05). Similar to endometrial carcinomas, molecular subtype stratification was generally superior to immune response in predicting outcomes.

CONCLUSIONS:

Subtype stratification is critical for better understanding of ENOC, in particular the distribution and prognostic significance of immune cell infiltrates. The role of B cells in the immune response within NSMP tumors warrants further study.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias do Endométrio / Carcinoma Endometrioide Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias do Endométrio / Carcinoma Endometrioide Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá